• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Conexeu Sciences Inc. - Common Stock (NQ:CNXU)

    3.950 +0.310 (+8.52%)
    Delayed Quote Updated: 4:00 PM EDT, Oct 15, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 600,641
    Open 3.660
    Bid (Size) 3.850 (300)
    Ask (Size) 3.960 (200)
    Prev. Close 3.640
    Today's Range 3.400 - 4.050
    52wk Range 3.050 - 18.79
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Let's have a look at the top gainers and losers in the middle of the day of today's session. ↗
    Via Chartmill
    News headline image
    Wound Care Stocks Are Posting Double-Digit Growth. Here’s Why.
    From Wall Street Investor
    Via GlobeNewswire

    Performance

    52-Week Range 79.0% below 52-week high
    3.950
    3.0552W Low 18.7952W High
    1 Week 9.4% below 1-week high
    3.301W Low 4.361W High

    Conexeu Sciences Inc. - Common Stock (CNXU) traded between $3.05 and $18.79 over the past 52 weeks and last traded at $3.95, 79.0% below its 52-week high. Over the past week it ranged between $3.30 and $4.36.

    Past 12 Months
    +14.5%
    -21.0%
    -64.7%
    -69.8%
    -69.8%
    -69.8%
    1W +$0.50
    1M -$1.05
    3M -$7.23
    6M -$9.12
    YTD -$9.12
    1Y -$9.12

    CNXU was -69.8% over the past year, -69.8% over six months, -69.8% year to date, +14.5% in the last week.

    12 Months vs Market
    CNXU
    -69.8%
    DIA
    +12.6%
    SPY
    +16.5%
    QQQ
    +21.7%
    IWM
    +11.0%

    Over the past 12 months CNXU returned -69.8% versus DIA (Dow) +12.6%, SPY (S&P 500) +16.5%, QQQ (Nasdaq 100) +21.7% and IWM (Russell 2000) +11.0%.

    Volume & Liquidity 2.55× 3-mo avg
    Today 600,641 3-mo avg 235.6K
    1W
    511.8K
    1M
    280.1K
    3M
    235.6K
    6M
    185.4K
    YTD
    185.4K
    1Y
    185.4K

    CNXU most recently traded 600,641 shares against a 3-month average daily volume of 235.6K.

    More News

    Read More
    News headline image
    A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.
    From Equity Insider
    Via GlobeNewswire
    News headline image
    The Biggest Winners Don't Compete in a Category. They Rewrite It. One Company Is Betting It Can Too.
    From American News Group
    Via GlobeNewswire
    News headline image
    The GLP-1 Boom Created a Tissue Gap Fillers Were Not Built For
    From USA News Group
    Via GlobeNewswire
    News headline image
    Cosmetic Surgery's Next Debate: Rebuild Tissue, Not Fill It
    From Biotech Insider
    Via GlobeNewswire
    News headline image
    Every Few Decades, Aesthetics Gets a New Category. One Preclinical Company Thinks Its Extra Cellular Matrix Platform Could Create the Next One
    From American News Group
    Via GlobeNewswire
    News headline image
    12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
    Via Benzinga
    News headline image
    A Weight-Loss Revolution Is Reshaping Bodies. This Preclinical Biotech Wants to Build What Comes Next
    From Energy Metal News
    Via GlobeNewswire
    News headline image
    A Nasdaq-Listed Regenerative Tissue Company Just Opened a Lab: The Next Step in Scaling a Platform Built for a NEW Aesthetics Opportunity
    From Biotech Insider
    Via GlobeNewswire
    News headline image
    The Aesthetics Giants Just Confirmed “Ozempic Face” Is Real — and a Newly Public Regenerative Player Wants to Compete for It
    From Biotech Insider
    Via GlobeNewswire
    News headline image
    Regenerative Medicine’s Next Chapter: Inside the Race to Make the Body Rebuild Itself
    From Biotech Insider
    Via GlobeNewswire
    News headline image
    The Quiet Revolution in Regenerative Medicine: From Replacing Tissue to Rebuilding It
    From World Street Intelligence
    Via GlobeNewswire
    News headline image
    A Fresh FDA Catalyst Is Putting Regenerative Wound Care in Focus
    From Equity Insider
    Via GlobeNewswire
    News headline image
    Before the IPO: 4 Companies That Rewarded Investors Who Got In Early ↗
    Via MarketBeat
    Topics Initial Public Offering
    News headline image
    After Fifty Years of Implants, a Newly Public Biotech Is Trying to Rebuild the Breast Instead
    From Biotech Insider
    Via GlobeNewswire
    News headline image
    The Newest Name on Nasdaq Wants to Help the Body Rebuild Itself
    From Energy Metal News
    Via GlobeNewswire
    News headline image
    A Reno Biotech Just Rang the Nasdaq Bell — Here’s Why the Whole Regenerative-Medicine Tape Is Worth Watching
    From World Street Intelligence
    Via GlobeNewswire
    News headline image
    Conexeu Sciences Commences Trading on Nasdaq Under Ticker Symbol "CNXU"
    Via Newsfile

    Frequently Asked Questions

    Is Conexeu Sciences Inc. - Common Stock publicly traded?
    Yes, Conexeu Sciences Inc. - Common Stock is publicly traded.
    What exchange does Conexeu Sciences Inc. - Common Stock trade on?
    Conexeu Sciences Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Conexeu Sciences Inc. - Common Stock?
    The ticker symbol for Conexeu Sciences Inc. - Common Stock is CNXU on the Nasdaq Stock Market
    What is the current price of Conexeu Sciences Inc. - Common Stock?
    The current price of Conexeu Sciences Inc. - Common Stock is 3.950
    When was Conexeu Sciences Inc. - Common Stock last traded?
    The last trade of Conexeu Sciences Inc. - Common Stock was at 10/15/26 04:00 PM ET
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.